Troglitazone , ≥96% , 97322-87-7
Synonym(s):
(±)-5-[4-[(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione;CS-045;Troglitazone - CAS 97322-87-7 - Calbiochem
| Pack Size | Price | Stock | Quantity |
| 10MG | RMB175.20 | In Stock |
|
| 50MG | RMB712.00 | In Stock |
|
| 100mg | RMB1199.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 184-186°C |
| Boiling point: | 657.0±55.0 °C(Predicted) |
| Density | 1.266±0.06 g/cm3(Predicted) |
| storage temp. | Inert atmosphere,Store in freezer, under -20°C |
| solubility | DMSO: 20 mg/mL |
| form | solid |
| pka | 6.34±0.50(Predicted) |
| color | white to yellow |
| Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
| InChI | InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28) |
| InChIKey | GXPHKUHSUJUWKP-UHFFFAOYSA-N |
| SMILES | S1C(CC2=CC=C(OCC3(C)OC4=C(C)C(C)=C(O)C(C)=C4CC3)C=C2)C(=O)NC1=O |
| CAS DataBase Reference | 97322-87-7(CAS DataBase Reference) |
Description and Uses
Rezulin was launched in Japan, the UK (subseqently withdrawn) and the US for treatment of type Ⅱ diabetes. Two approaches, four steps and six steps, converge on 6-acetoxy-2-(4-aminophenoxymethyl)-2,5,7,8-tetramethylchroman which can be elaborated in two steps to Rezulin. It is the first of a new class of thiazolidenediones for NIDDM that reduces glucose concentrations without effecting insulin secretion. It binds to peroxisome proliferator-activated receptor gamma (PPARγ) thus activating this nuclear receptor which then influences carbohydrate metabolism. This is accomplished by increasing insulin sensitivity by upregulating glucose transporter (Glut1 and/or Glut4) expression without affecting the number or affinity of insulin receptors. There is also an increase in hepatic glycogen synthase activity which enhances glucose utilization and a reduction in hepatic gluconeogenesis by inhibiting fructose-1 ,&bisphosphatase. Pancreatic islet cell destruction is prevented. It reduces serum triglycerides because PPARγ causes fibroblasts to differentiate into adipocytes and does not activate RARα. It has a half-life of 9 h and is metabolized into three compounds having no activity.
Troglitazone is an an oral hypoglycemic agent which improves insulin sensitivity and decreases hepatic glucose production. Antidiabetic.
Safety
| Safety Statements | 22-24/25 |
| WGK Germany | 2 |
| RTECS | XJ5813130 |
| HS Code | 29145090 |
